The estimated Net Worth of Marc R Schneebaum is at least $16.1 Millón dollars as of 11 June 2018. Mr. Schneebaum owns over 10,099 units of Madrigal Pharmaceuticals Inc stock worth over $9,708,644 and over the last 8 years he sold MDGL stock worth over $2,903,059. In addition, he makes $3,532,650 as Chief Financial Officer y Senior Vice President at Madrigal Pharmaceuticals Inc.
Sign up
Mr. Schneebaum MDGL stock SEC Form 4 insiders trading
Marc has made over 1 trades of the Madrigal Pharmaceuticals Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he sold 10,099 units of MDGL stock worth $2,903,059 on 11 June 2018.
The largest trade he's ever made was selling 10,099 units of Madrigal Pharmaceuticals Inc stock on 11 June 2018 worth over $2,903,059. On average, Marc trades about 1,262 units every 0 days since 2016. As of 11 June 2018 he still owns at least 41,668 units of Madrigal Pharmaceuticals Inc stock.
You can see the complete history of Mr. Schneebaum stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Marc Schneebaum biography
Marc R. Schneebaum serves as Chief Financial Officer, Senior Vice President of the Company. Mr. Schneebaum served as Synta’s Senior Vice President and Chief Financial Officer from December 2014 through the Merger in July 2016. Mr. Schneebaum has over 25 years of experience in the biotechnology and healthcare sector. Prior to joining Synta, Mr. Schneebaum served as a consultant in the healthcare industry. From 2011 to 2013, Mr. Schneebaum served as President, Chief Executive Officer and a director of Predictive BioSciences, Inc., a commercial stage cancer diagnostics company. From 1997 to 2010, he served as President, Chief Executive Officer, and a director of Sensors for Medicine and Science, Inc., an emerging medical technology company. From 1991 to 1997, he served as Senior Vice President, Finance, Business Development and Administration, and Chief Financial Officer of Genetic Therapy, Inc., a biotechnology company (acquired by Sandoz/Novartis). From 1987 to 1991, Mr. Schneebaum was a Vice President at Alex. Brown & Sons Incorporated, a leading investment banking firm, where he participated in a variety of finance and strategic assignments. Mr. Schneebaum began his career in the accounting and auditing group at KPMG LLP, advancing to Senior Manager in the management consulting group. Mr. Schneebaum served as a director of GenVec, Inc., a publicly-held biopharmaceutical company acquired by Intrexon Corporation, from 2007 to 2017. Mr. Schneebaum earned his B.S. in Business Administration, Accounting from the University of Maryland.
What is the salary of Marc Schneebaum?
As the Chief Financial Officer y Senior Vice President of Madrigal Pharmaceuticals Inc, the total compensation of Marc Schneebaum at Madrigal Pharmaceuticals Inc is $3,532,650. There are 3 executives at Madrigal Pharmaceuticals Inc getting paid more, with Paul Friedman having the highest compensation of $6,093,190.
How old is Marc Schneebaum?
Marc Schneebaum is 65, he's been the Chief Financial Officer y Senior Vice President of Madrigal Pharmaceuticals Inc since 2014. There are 7 older and 10 younger executives at Madrigal Pharmaceuticals Inc. The oldest executive at Madrigal Pharmaceuticals Inc is David Milligan, 79, who is the Independent Director.
What's Marc Schneebaum's mailing address?
Marc's mailing address filed with the SEC is C/O MADRIGAL PHARMACEUTICALS, INC., 200 BARR HARBOR DRIVE, SUITE 200, WEST CONSHOHOCKEN, PA, 19428.
Insiders trading at Madrigal Pharmaceuticals Inc
Over the last 8 years, insiders at Madrigal Pharmaceuticals Inc have traded over $471,222,585 worth of Madrigal Pharmaceuticals Inc stock and bought 443,785 units worth $79,114,183 . The most active insiders traders include Bros. Advisors Lp667, L.P.B..., Paul A Friedman y Bros. Advisors Lp667, L.P.B.... On average, Madrigal Pharmaceuticals Inc executives and independent directors trade stock every 56 days with the average trade being worth of $20,602,093. The most recent stock trade was executed by William John Sibold on 9 September 2024, trading 6,363 units of MDGL stock currently worth $1,551,490.
What does Madrigal Pharmaceuticals Inc do?
madrigal pharmaceuticals inc. is a biotechnology company based out of calle laguna del marquesado nª 19, nave 16 edificio adriana 1ª planta, polígono industrial la resina (villaverde), madrid, community of madrid, spain.
What does Madrigal Pharmaceuticals Inc's logo look like?
Complete history of Mr. Schneebaum stock trades at Madrigal Pharmaceuticals Inc
Madrigal Pharmaceuticals Inc executives and stock owners
Madrigal Pharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
Paul Friedman,
Chairman of the Board, Chief Executive Officer -
Rebecca Taub,
President of Research and Development, Chief Medical Officer, Director -
Brian Lynch,
Senior Vice President, General Counsel -
Marc Schneebaum,
Chief Financial Officer, Senior Vice President -
James Daly,
Independent Director -
Dr. Paul A. Friedman M.D.,
Chairman & CEO -
Dr. Rebecca A. Taub M.D.,
Founder, Chief Medical Officer, Pres of R&D and Director -
Remy Sukhija,
Sr. VP & Chief Commercial Officer -
Brian J. Lynch J.D.,
Sr. VP & Gen. Counsel -
Brian J. Lynch,
Sr. VP & Gen. Counsel -
Kenneth Bate,
Independent Director -
Richard Levy,
Independent Director -
Keith Gollust,
Independent Director -
David Milligan,
Independent Director -
Frederick Craves,
Lead Independent Director -
Remy Sukhija,
Senior Vice President, Chief Commercial Officer -
Edward Chiang,
Sr. VP of Clinical & Technical Operations -
Dr. Stephen Dodge M.B.A., Pharm.D.,
Sr. VP & Global Head of Medical Affairs -
Dr. Robert E. Waltermire Ph.D.,
Chief Pharmaceutical Devel. Officer -
Thomas W. Hare,
Sr. VP of Clinical Management -
Dr. Kianoush Motesharei Ph.d.,
Sr. VP of Bus. & Corp. Devel. -
Alex G. Howarth,
Chief Financial Officer -
Bros. Advisors Lp667, L.P.B...,
-
Bros. Advisors Lp667, L.P.B...,
-
Chen Schor,
Former President and CEO -
Wendy E Rieder,
Former SVP, Gen. Counsel -
City Capital Llc Bay,
Director -
City Capital Llc Bay City C...,
-
Alex G. Howarth,
Chief Financial Officer -
Robert E. Waltermire,
Senior VP, Chief Pharma Dev. -
Bros. Advisors Lp Baker,
-
Shannon T Kelley,
General Counsel -
William John Sibold,
President and CEO -
Carole Huntsman,
Chief Commercial Officer -
Fred B Craves,